ALPA vs NATCOPHARM: Stock Comparison

Alpa Laboratories Limited vs Natco Pharma Limited

Live data: 22 July 2026, 2:57 PM IST • Source: NSE and company filings

Natco Pharma Limited is the larger company by market capitalisation. Alpa Laboratories Limited shows a lower P/E, faster revenue growth and lower leverage, while Natco Pharma Limited shows a higher ROE, a higher dividend yield and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Alpa Laboratories Limited and Natco Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ALPA is more favourable on 7 of 13 scored metrics and NATCOPHARM on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NATCOPHARM is the larger company
₹16,782 Cr vs ₹142 Cr
P/E Ratio
ALPA has a lower P/E
12.09x vs 12.12x
P/B Ratio
ALPA has a lower P/B
0.77x vs 1.86x
EPS
NATCOPHARM has higher earnings per share
₹79.24 vs ₹7.14
Dividend Yield
NATCOPHARM has a higher dividend yield
0.52% vs 0%
Revenue Growth (TTM YoY)
ALPA has faster revenue growth
-21.4% vs -39.6%
EPS Growth (TTM YoY)
ALPA has faster EPS growth
0% vs -34.1%
Qtr Sales Growth
ALPA has stronger quarterly sales growth
-21.3% vs -39.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricALPANATCOPHARM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricALPANATCOPHARM
Live Price₹66.98₹936.7
Day Change-0.98%-2.62%
Volume6,9583.38 L
52-Week High₹105.51₹1,226.8
52-Week Low₹46.1₹789
Distance from 52W High-36.52%-23.65%

Valuation

MetricALPANATCOPHARM
Market Cap₹142 Cr₹16,782 Cr
P/E Ratio12.09x12.12x
P/B Ratio0.77x1.86x
EPS₹7.14₹79.24
Book Value₹32.34₹514.92
Dividend Yield0%0.52%

Growth

MetricALPANATCOPHARM
Revenue Growth (TTM YoY)-21.4%-39.6%
EPS Growth (TTM YoY)0%-34.1%
Qtr Sales Growth-21.3%-39.5%
Qtr Profit Growth165%-34.1%

Profitability & Leverage

MetricALPANATCOPHARM
ROE8.39%16.9%
ROCE9.42%17.1%
Net Margin14.33%34.78%
Operating Margin3.11%35.2%
Debt to Equity0.01x0.08x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricALPANATCOPHARM
Promoter Holding57.19%49.14%
FII Holding0.35% 0.03 pp16.99% 0.38 pp
DII Holding0.07% 0.07 pp5.62% 0.16 pp
Public Holding42.39% 0.04 pp27.97% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alpa Laboratories Limited and Natco Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.